{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-001308","form_type":"8-K","ticker":"SHPH","cik":"0001757499","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","filed_at":"2023-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.428345+00:00","generated_at":"2026-06-20T16:05:29.885731+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Shuttle Pharmaceuticals issues $4.3M convertible note and warrant, receives $4M gross proceeds","bullets":["Issued $4.3M senior secured convertible note to Alto Opportunity Master Fund; gross proceeds $4.0M.","Warrant to purchase 1,018,079 shares at $2.35/share, exercisable for 4 years, potential additional $2.4M.","Note amortizes over 26 months, 5% interest; conversion price tied to discounted VWAP formulas.","Full security interest on all assets and IP; springing deposit account control if default.","Boustead Securities placement agent received $320,000 cash and a warrant for 71,266 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-001308","json":"https://secwatch.observer/filing/0001493152-23-001308.json","markdown":"https://secwatch.observer/filing/0001493152-23-001308.md","text":"https://secwatch.observer/filing/0001493152-23-001308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/0001493152-23-001308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T16:05:29.885731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f5cf2ef5fbf8411aa1618cd06acc336a8c5ab94","claim":"Shuttle Pharmaceuticals Holdings, Inc. entered into SPA with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B valued at $4.3 million convertible note (effective 2023-01-11).","evidence_excerpt":"On January 11, 2023, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, a Cayman entity (the “Investor”), pursuant to which the Company sold to the Investor a $4.3 million convertible note (the “Convertible Note”) and warrant (the “Warrant”) to purchase 1,018,079 shares of common stock, par value $0.00001 per share (“Common Stock”), in exchange for gross proceeds of $4.0 million (the “Investment Amount”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/0001493152-23-001308-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B"},{"label":"Value","value":"$4.3 million convertible note"},{"label":"Effective","value":"2023-01-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}